Hillevax is currently the subject of a class action lawsuit, filed on behalf of shareholders, regarding alleged violations of federal securities laws.
If you have investment losses with HilleVax, Inc., please contact Silver Law Group at (800) 975-4345 or at ssilver@silverlaw.com. The deadline to apply to be a lead plaintiff (class representative) is August 5, 2024.
Hillevax, Inc. is an American biopharmaceutical company that was founded in 2019. It specializes in developing and manufacturing novel vaccines, such as a vaccine for the norovirus.
On July 8, 2024, Hillevax released its results from its NEST-IN1 Phase 2b clinical trial for HIL-214, a vaccine tested in infants. The study failed to achieve its primary goal of preventing moderate to severe norovirus-induced gastroenteritis. Additionally, no benefits were observed in secondary outcome measures. As a result, HilleVax’s stock price plummeted from $12.42 per share to $1.64.
Silver Law Group is currently investigating whether Hillevax omitted material information or made false or misleading statements to investors.
Silver Law Group is a nationally recognized law firm representing victims of securities and investment fraud. Our attorneys represent investors nationwide in class action lawsuits against issuers in state and federal court for violations of the federal securities laws and breach of fiduciary duties.
Scott Silver, Silver Law Group’s managing partner is the Chairman of the Securities and Financial Fraud Group of the American Association of Justice, a member of the National Trial Lawyer’s Class Action Group, and he routinely speaks at industry conferences about securities and investment fraud. Contact us for a no-cost consultation at ssilver@silverlaw.com or call (800) 975-4345.
Fill out the contact form or call us at (800) 975-4345 to schedule your free consultation.
